Essa Pharma
Investors/Media

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

Latest News
May 10, 2022
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a...

Apr 26, 2022
ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...

Apr 8, 2022
ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders...

View All News

View All

Stock Performance

Last Price

Change

Volume

NASDAQEPIX
Learn More

Investor & Media Contacts

INVESTORS
Xuan Yang
Solebury Trout
xyang@soleburytrout.com

MEDIA
Zara Lockshin
Solebury Trout
zlockshin@soleburytrout.com